SE0302487D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0302487D0
SE0302487D0 SE0302487A SE0302487A SE0302487D0 SE 0302487 D0 SE0302487 D0 SE 0302487D0 SE 0302487 A SE0302487 A SE 0302487A SE 0302487 A SE0302487 A SE 0302487A SE 0302487 D0 SE0302487 D0 SE 0302487D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
racemates
tautomers
Prior art date
Application number
SE0302487A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Hansen
Hans Loenn
Antonios Nikitidis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0302487(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302487A priority Critical patent/SE0302487D0/xx
Publication of SE0302487D0 publication Critical patent/SE0302487D0/xx
Priority to TW093127678A priority patent/TW200526579A/zh
Priority to PCT/SE2004/001336 priority patent/WO2005026124A1/en
Priority to AT04775439T priority patent/ATE420861T1/de
Priority to ES04775439T priority patent/ES2319300T3/es
Priority to BRPI0414570-4A priority patent/BRPI0414570A/pt
Priority to UAA200602252A priority patent/UA84878C2/ru
Priority to JP2006526856A priority patent/JP2007505902A/ja
Priority to KR1020067005458A priority patent/KR20060096995A/ko
Priority to EP04775439A priority patent/EP1663974B1/en
Priority to US10/572,640 priority patent/US20070043036A1/en
Priority to HK06109477.7A priority patent/HK1089167B/en
Priority to AU2004272485A priority patent/AU2004272485B2/en
Priority to DE602004019110T priority patent/DE602004019110D1/de
Priority to RU2006112427/04A priority patent/RU2348617C2/ru
Priority to CNB2004800275174A priority patent/CN100439339C/zh
Priority to CA002538410A priority patent/CA2538410A1/en
Priority to MXPA06002723A priority patent/MXPA06002723A/es
Priority to UY28513A priority patent/UY28513A1/es
Priority to ARP040103354A priority patent/AR046083A1/es
Priority to SA4250300A priority patent/SA04250300B1/ar
Priority to IL173986A priority patent/IL173986A0/en
Priority to CO06026211A priority patent/CO5670357A2/es
Priority to ZA200602262A priority patent/ZA200602262B/xx
Priority to IS8394A priority patent/IS8394A/is
Priority to NO20061700A priority patent/NO20061700L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
SE0302487A 2003-09-18 2003-09-18 Novel compounds SE0302487D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds
TW093127678A TW200526579A (en) 2003-09-18 2004-09-13 Novel compounds
MXPA06002723A MXPA06002723A (es) 2003-09-18 2004-09-15 Derivados de 2-piridona como inhibidores de neutrofilo elastasa y su uso.
UY28513A UY28513A1 (es) 2003-09-18 2004-09-15 Nuevos compuestos
HK06109477.7A HK1089167B (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
DE602004019110T DE602004019110D1 (de) 2003-09-18 2004-09-15 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
ES04775439T ES2319300T3 (es) 2003-09-18 2004-09-15 Derivados de 2-piridona como inhibidores de elastasa neutrofila y su uso.
BRPI0414570-4A BRPI0414570A (pt) 2003-09-18 2004-09-15 derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
UAA200602252A UA84878C2 (ru) 2003-09-18 2004-09-15 Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
JP2006526856A JP2007505902A (ja) 2003-09-18 2004-09-15 好中球エラスターゼ阻害剤としての２−ピリドン誘導体およびその使用
KR1020067005458A KR20060096995A (ko) 2003-09-18 2004-09-15 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도
EP04775439A EP1663974B1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
US10/572,640 US20070043036A1 (en) 2003-09-18 2004-09-15 2-Pyridone derivatives as neutrophil elastase inhibitors and their use
PCT/SE2004/001336 WO2005026124A1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
AU2004272485A AU2004272485B2 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as neutrophil elastase inhibitors and their use
AT04775439T ATE420861T1 (de) 2003-09-18 2004-09-15 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
RU2006112427/04A RU2348617C2 (ru) 2003-09-18 2004-09-15 Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
CNB2004800275174A CN100439339C (zh) 2003-09-18 2004-09-15 用作嗜中性白细胞弹性蛋白酶抑制剂的2-吡啶酮衍生物及其用途
CA002538410A CA2538410A1 (en) 2003-09-18 2004-09-15 2-pyridone derivatives as netrophil elastase inhibitors and their use
ARP040103354A AR046083A1 (es) 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos
SA4250300A SA04250300B1 (ar) 2003-09-18 2004-09-18 مشتقات 2_ بيريدون تعمل كمثبطات لانزيم ايلاستيز النتيروفيل واستخدامها
IL173986A IL173986A0 (en) 2003-09-18 2006-02-27 2-pyridone derivatives as netrophil elastase inhibitors and their use
CO06026211A CO5670357A2 (es) 2003-09-18 2006-03-15 Derivados de 2-piridona como inhibidores de elastasa neutrofila y su uso
ZA200602262A ZA200602262B (en) 2003-09-18 2006-03-17 2-Pyridone derivatives as neutrophil elastase inhibitors and their use
IS8394A IS8394A (is) 2003-09-18 2006-03-31 2-pýridónafleiður sem daukyrningselastasatálmar og notkun þeirra
NO20061700A NO20061700L (no) 2003-09-18 2006-04-18 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
SE0302487D0 true SE0302487D0 (sv) 2003-09-18

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Country Status (25)

Country Link
US (1) US20070043036A1 (enExample)
EP (1) EP1663974B1 (enExample)
JP (1) JP2007505902A (enExample)
KR (1) KR20060096995A (enExample)
CN (1) CN100439339C (enExample)
AR (1) AR046083A1 (enExample)
AT (1) ATE420861T1 (enExample)
AU (1) AU2004272485B2 (enExample)
BR (1) BRPI0414570A (enExample)
CA (1) CA2538410A1 (enExample)
CO (1) CO5670357A2 (enExample)
DE (1) DE602004019110D1 (enExample)
ES (1) ES2319300T3 (enExample)
IL (1) IL173986A0 (enExample)
IS (1) IS8394A (enExample)
MX (1) MXPA06002723A (enExample)
NO (1) NO20061700L (enExample)
RU (1) RU2348617C2 (enExample)
SA (1) SA04250300B1 (enExample)
SE (1) SE0302487D0 (enExample)
TW (1) TW200526579A (enExample)
UA (1) UA84878C2 (enExample)
UY (1) UY28513A1 (enExample)
WO (1) WO2005026124A1 (enExample)
ZA (1) ZA200602262B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
ES2600460T3 (es) * 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US20070104699A1 (en) * 2005-09-29 2007-05-10 University Of Alberta Compositions for and methods of granzyme B inhibition
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2535330A3 (en) 2006-10-23 2012-12-26 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
SI2089364T1 (sl) 2006-11-08 2013-10-30 Bristol-Myers Squibb Company Spojine piridinona
EP2217591A4 (en) 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
DK2229358T3 (da) 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
BRPI0906444B8 (pt) 2008-01-23 2021-05-25 Bristol Myers Squibb Co compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
CA2752693A1 (en) 2009-02-17 2010-08-26 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010302420B2 (en) * 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011071730A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
MY167216A (en) 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
UA115320C2 (uk) 2011-12-09 2017-10-25 К'Єзі Фармачеутічі С.П.А. Інгібітори кінази
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
JP6532599B2 (ja) 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
JP7034942B2 (ja) 2016-05-05 2022-03-14 エフ．ホフマン－ラ ロシュ アーゲー ピラゾール誘導体、その組成物及び治療的使用
CN109890817B (zh) 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
CR20190310A (es) 2016-12-29 2019-08-21 Hoffmann La Roche Compuestos de pirazolopirimidina y métodos de uso de los mismos
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
MX387969B (es) 2017-05-22 2025-03-19 Hoffmann La Roche Composiciones y compuestos terapéuticos, y métodos para su uso.
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP3740488A1 (en) 2018-01-15 2020-11-25 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds as jak inhibitors
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
PH12021552998A1 (en) 2019-06-18 2023-08-14 Hoffmann La Roche Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
IL297211B2 (en) 2020-04-16 2025-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
RU2140917C1 (ru) * 1993-11-19 1999-11-10 Парк, Дэвис энд Компани Производные 5,6-дигидропирона и фармацевтическая композиция на их основе
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
KR100828982B1 (ko) * 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
DE60214428T2 (de) * 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
IS8394A (is) 2006-03-31
RU2348617C2 (ru) 2009-03-10
BRPI0414570A (pt) 2006-11-07
JP2007505902A (ja) 2007-03-15
ES2319300T3 (es) 2009-05-06
SA04250300B1 (ar) 2008-09-07
CN100439339C (zh) 2008-12-03
KR20060096995A (ko) 2006-09-13
AU2004272485A1 (en) 2005-03-24
NO20061700L (no) 2006-04-18
UY28513A1 (es) 2005-04-29
EP1663974B1 (en) 2009-01-14
CN1856467A (zh) 2006-11-01
CO5670357A2 (es) 2006-08-31
EP1663974A1 (en) 2006-06-07
CA2538410A1 (en) 2005-03-24
MXPA06002723A (es) 2006-06-06
RU2006112427A (ru) 2007-11-10
ATE420861T1 (de) 2009-01-15
IL173986A0 (en) 2006-07-05
ZA200602262B (en) 2007-07-25
TW200526579A (en) 2005-08-16
AU2004272485B2 (en) 2008-03-13
WO2005026124A1 (en) 2005-03-24
US20070043036A1 (en) 2007-02-22
UA84878C2 (ru) 2008-12-10
DE602004019110D1 (de) 2009-03-05
AR046083A1 (es) 2005-11-23
HK1089167A1 (en) 2006-11-24

Similar Documents

Publication Publication Date Title
SE0302487D0 (sv) Novel compounds
SE0302324D0 (sv) Novel compounds
SE0302486D0 (sv) Novel compounds
SE0302323D0 (sv) Novel compounds
TW200500341A (en) Novel compounds
SE0202463D0 (sv) Novel compounds
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20044995L (no) Heterosykliske forbindelser
SE0302139D0 (sv) Novel compounds
SE0203304D0 (sv) Novel Coumpounds
SE0302756D0 (sv) Novel Compounds
SE0303280D0 (sv) Novel compounds
SE9803773D0 (sv) Compounds
SE0202461D0 (sv) Novel compounds
SE0102641D0 (sv) Novel compounds
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
SE0403118D0 (sv) New compounds 2
SE9904676D0 (sv) Novel compounds
SE0102640D0 (sv) Novel compounds
SE0103325D0 (sv) Novel compounds
NO20042729L (no) Heksasykliske forbindelser
SE0403117D0 (sv) New compounds 1
SE0302120D0 (sv) Novel compounds